CONNECT WITH US
HealthTech

HealthTech

Researchers identify strategy to make pediatric bone cancers more vulnerable to immunotherapy

Medical Xpress logo

Published on

Add as a preferred source on Google
Researchers identify strategy to make pediatric bone cancers more vulnerable to immunotherapy

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Ewing sarcoma is a rare and debilitating type of bone cancer affecting young adults and children. Despite intensive treatment with chemotherapy, surgery and radiation, many children do not overcome the disease.

Pediatric oncologists Ian Davis, M.D., Ph.D., and Justin Sperlazza, M.D., Ph.D., at the UNC School of Medicine and UNC Lineberger Comprehensive Cancer Center are working to expand treatment options and advance studies of pediatric solid tumors with the latest immunotherapies, like chimeric antigen receptor T-cell (CAR T-cell) therapy, which trains a patient's immune system to target and eliminate tumor cells.

In a new paper published in Molecular Cancer Therapeutics, Davis and Sperlazza identified drugs that make Ewing sarcoma cells more vulnerable to CAR T-cell therapy. The preclinical findings could help guide future clinical trials for children and young adults with sarcomas.

"New therapeutic strategies are really needed for patients with bone cancer who either don't respond to upfront therapy or experience relapse of the disease," said Sperlazza, who is first author on the paper. "Now that we know that our strategy works, we believe that we are on the cusp of getting this combination therapy to clinical trials."

D. Savoldo has been developing the next generation of CAR T cells that target GD2 , a molecule found on the surface of some cancer cells. GD2 acts as a beacon to help immunotherapies recognize and target tumors.


Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.